{"id":"pm8002","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, PM8002 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"PM8002 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:13.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07221357","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Untreated, Unresectable, or Metastatic Colorectal Cancer","enrollment":990},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT06618287","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-04","conditions":"Lung Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT06841055","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-03-03","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07297212","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-01-15","conditions":"Recurrent Glioblastoma","enrollment":75},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT07221149","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-03-31","conditions":"Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","enrollment":690},{"nctId":"NCT06712355","phase":"PHASE3","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-02-03","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":621},{"nctId":"NCT07255404","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-04","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":105},{"nctId":"NCT07133750","phase":"PHASE2","title":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2025-08","conditions":"CRC (Colorectal Cancer)","enrollment":40},{"nctId":"NCT05756972","phase":"PHASE2","title":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2023-06-26","conditions":"NSCLC","enrollment":64},{"nctId":"NCT05844150","phase":"PHASE2","title":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2023-06-01","conditions":"SCLC","enrollment":50},{"nctId":"NCT05864105","phase":"PHASE2","title":"PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2022-04-22","conditions":"Hepatocellular Carcinoma","enrollment":35},{"nctId":"NCT06419621","phase":"PHASE3","title":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","status":"RECRUITING","sponsor":"Biotheus Inc.","startDate":"2024-06-11","conditions":"Triple Negative Breast Cancer(TNBC)","enrollment":360},{"nctId":"NCT05918133","phase":"PHASE1, PHASE2","title":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2022-07-01","conditions":"TNBC","enrollment":42},{"nctId":"NCT06837948","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-02-18","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT06616532","phase":"PHASE3","title":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Biotheus Inc.","startDate":"2024-11-13","conditions":"SCLC","enrollment":404},{"nctId":"NCT05879055","phase":"PHASE2","title":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","status":"RECRUITING","sponsor":"Biotheus Inc.","startDate":"2023-05-17","conditions":"Neuroendocrine Neoplasm","enrollment":60},{"nctId":"NCT05879068","phase":"PHASE2","title":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2022-05-27","conditions":"SCLC","enrollment":99},{"nctId":"NCT06584071","phase":"PHASE1, PHASE2","title":"A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC","status":"NOT_YET_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2024-12","conditions":"HCC, Liver Cancer","enrollment":140},{"nctId":"NCT05918445","phase":"PHASE1, PHASE2","title":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Biotheus Inc.","startDate":"2021-03-09","conditions":"Malignant Neoplasm","enrollment":380},{"nctId":"NCT05918107","phase":"PHASE2","title":"A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM","status":"RECRUITING","sponsor":"Biotheus Inc.","startDate":"2022-08-13","conditions":"MPM","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BNT327"],"phase":"phase_3","status":"active","brandName":"PM8002","genericName":"PM8002","companyName":"Biotheus Inc.","companyId":"biotheus-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PM8002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}